Triglycerides

FDA Issues CRL Rejecting Waylivra Approval for Familial Chylomicronemia Syndrome

FDA Issues CRL Rejecting Waylivra Approval for Familial Chylomicronemia Syndrome

By

"We are extremely disappointed with the FDA's decision. We continue to feel strongly that Waylivra demonstrates a favorable benefit/risk profile in people with FCS," said Akcea CEO, Paula Soteropoulos.

Patient Connectivity Benefits Familial Chylomicronemia Syndrome

Patient Connectivity Benefits Familial Chylomicronemia Syndrome

By

Patients with familial chylomicronemia syndrome who were actively connected were also 3 times as likely to report "high" or "extremely high" motivation in managing their own health.

FDA Committee in Favor of Waylivra for Rare Metabolic Lipid Disorder

FDA Committee in Favor of Waylivra for Rare Metabolic Lipid Disorder

By

Antisense technology refers to the use of synthetic nucleic acid sequences to interrupt specific protein production by targeting the corresponding messenger RNA that encodes that protein.

Sign Up for Free e-Newsletters